How AI Helps Fill the Labor Gap in Treating Rare Diseases

Modern biotechnology possesses the incredible power to edit human genes and design entirely new medicines. Despite these advanced capabilities, thousands of rare diseases remain without a cure. According to leaders in the medical field, the missing piece for many years has been a severe lack of skilled scientists and researchers. Artificial intelligence is now emerging as a powerful tool that multiplies what human scientists can achieve. This technology allows them to tackle complex problems that the industry has long ignored or been unable to solve.

Executives from two leading biotech companies, Insilico Medicine and GenEditBio, explained this significant shift in approach at a recent technology conference. They believe that artificial intelligence is essential for overcoming the industry's current talent shortage. Furthermore, they argue that AI is the key to finally bringing life-saving treatments to patients suffering from neglected conditions.

Speaking at the Web Summit Qatar conference, Alex Aliper, the president of Insilico Medicine, described his company's ambitious goal. They aim to develop what he calls "pharmaceutical superintelligence." To achieve this, the company recently launched a platform known as the "MMAI Gym." This platform is designed to train general-purpose artificial intelligence models, similar to chatbots like ChatGPT. The goal is to train these models to perform with the same precision as specialized scientific models.

The ultimate objective is to build a single, versatile artificial intelligence model. This model could handle many different tasks related to drug discovery simultaneously. It promises to do so with an accuracy greater than what humans can achieve on their own. Aliper stressed the urgent need for such advanced technology in the current landscape.

"We really need this technology to increase the productivity of our pharmaceutical industry and tackle the shortage of labor and talent," Aliper said in an interview. "There are still thousands of diseases without a cure, without any treatment options, and there are thousands of rare disorders which are neglected. So we need more intelligent systems to tackle that problem."